ZA200103620B - Utilization of inhibitors of the KQT1 channel in order to produce a medicament for treating diseases which are caused by parasitic helminths and extoparasites. - Google Patents
Utilization of inhibitors of the KQT1 channel in order to produce a medicament for treating diseases which are caused by parasitic helminths and extoparasites. Download PDFInfo
- Publication number
- ZA200103620B ZA200103620B ZA200103620A ZA200103620A ZA200103620B ZA 200103620 B ZA200103620 B ZA 200103620B ZA 200103620 A ZA200103620 A ZA 200103620A ZA 200103620 A ZA200103620 A ZA 200103620A ZA 200103620 B ZA200103620 B ZA 200103620B
- Authority
- ZA
- South Africa
- Prior art keywords
- atoms
- hydrogen
- alkyl
- group
- methyl
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims description 19
- 239000003814 drug Substances 0.000 title claims description 16
- 244000000013 helminth Species 0.000 title claims description 16
- 201000010099 disease Diseases 0.000 title claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 14
- 230000003071 parasitic effect Effects 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 claims description 386
- 239000001257 hydrogen Substances 0.000 claims description 376
- 229910052739 hydrogen Inorganic materials 0.000 claims description 376
- -1 methoxy, sulfamoyl Chemical group 0.000 claims description 302
- 125000000217 alkyl group Chemical group 0.000 claims description 238
- 150000002431 hydrogen Chemical class 0.000 claims description 219
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 219
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 208
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 182
- 229910052731 fluorine Inorganic materials 0.000 claims description 152
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 151
- 229910052794 bromium Inorganic materials 0.000 claims description 134
- 229910052801 chlorine Inorganic materials 0.000 claims description 132
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 130
- 125000001424 substituent group Chemical group 0.000 claims description 130
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 119
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 106
- 125000001544 thienyl group Chemical group 0.000 claims description 86
- 125000002947 alkylene group Chemical group 0.000 claims description 73
- 125000005009 perfluoropropyl group Chemical group FC(C(C(F)(F)F)(F)F)(F)* 0.000 claims description 59
- 125000004076 pyridyl group Chemical group 0.000 claims description 57
- 125000002883 imidazolyl group Chemical group 0.000 claims description 54
- 125000000623 heterocyclic group Chemical group 0.000 claims description 52
- 229910052740 iodine Inorganic materials 0.000 claims description 51
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 39
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 35
- 125000004429 atom Chemical group 0.000 claims description 33
- 150000003839 salts Chemical class 0.000 claims description 31
- 150000001875 compounds Chemical class 0.000 claims description 30
- 125000005936 piperidyl group Chemical group 0.000 claims description 24
- 125000005956 isoquinolyl group Chemical group 0.000 claims description 21
- 125000005493 quinolyl group Chemical group 0.000 claims description 21
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 14
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 13
- 244000078703 ectoparasite Species 0.000 claims description 13
- 125000004423 acyloxy group Chemical group 0.000 claims description 10
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 241000238421 Arthropoda Species 0.000 claims description 7
- 241000237852 Mollusca Species 0.000 claims description 7
- 125000002252 acyl group Chemical group 0.000 claims description 7
- 230000003032 phytopathogenic effect Effects 0.000 claims description 7
- 241000244206 Nematoda Species 0.000 claims description 6
- 125000003016 chromanyl group Chemical class O1C(CCC2=CC=CC=C12)* 0.000 claims description 6
- 230000009471 action Effects 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 4
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 claims description 3
- 125000004434 sulfur atom Chemical group 0.000 claims description 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 3
- 125000003342 alkenyl group Chemical group 0.000 claims 9
- 125000002541 furyl group Chemical group 0.000 claims 8
- 229910052760 oxygen Inorganic materials 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 5
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 4
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 4
- 101100379080 Emericella variicolor andB gene Proteins 0.000 claims 3
- 125000004442 acylamino group Chemical group 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 3
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 3
- 229920006395 saturated elastomer Polymers 0.000 claims 3
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 125000002837 carbocyclic group Chemical group 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000004404 heteroalkyl group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000002924 primary amino group Chemical class [H]N([H])* 0.000 claims 2
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 1
- 101100219382 Caenorhabditis elegans cah-2 gene Proteins 0.000 claims 1
- 229910003204 NH2 Inorganic materials 0.000 claims 1
- 229910006069 SO3H Inorganic materials 0.000 claims 1
- 125000006323 alkenyl amino group Chemical group 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000005257 alkyl acyl group Chemical group 0.000 claims 1
- 125000005277 alkyl imino group Chemical group 0.000 claims 1
- 125000004103 aminoalkyl group Chemical group 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims 1
- 125000004417 unsaturated alkyl group Chemical group 0.000 claims 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 1
- 241001465754 Metazoa Species 0.000 description 7
- 244000045947 parasite Species 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 5
- 230000003288 anthiarrhythmic effect Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 239000003416 antiarrhythmic agent Substances 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 238000009304 pastoral farming Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 241000238876 Acari Species 0.000 description 1
- 240000007818 American spikenard Species 0.000 description 1
- 235000004446 Aralia racemosa Nutrition 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061217 Infestation Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000000895 acaricidal effect Effects 0.000 description 1
- 239000000642 acaricide Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 239000000921 anthelmintic agent Substances 0.000 description 1
- 229940124339 anthelmintic agent Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 239000013057 ectoparasiticide Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000002336 repolarization Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19858253A DE19858253A1 (de) | 1998-12-17 | 1998-12-17 | Verwendung von Inhibitoren des KQt1-Kanals zur Herstellung eines Medikaments zur Behandlung von Krankheiten, die durch Helminthen und Ektoparasiten hervorgerufen werden |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200103620B true ZA200103620B (en) | 2002-06-04 |
Family
ID=7891421
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200103620A ZA200103620B (en) | 1998-12-17 | 2001-05-04 | Utilization of inhibitors of the KQT1 channel in order to produce a medicament for treating diseases which are caused by parasitic helminths and extoparasites. |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US6335363B1 (pt) |
| EP (1) | EP1140042B1 (pt) |
| JP (1) | JP2002532412A (pt) |
| KR (1) | KR20010089574A (pt) |
| CN (1) | CN1170528C (pt) |
| AR (1) | AR021690A1 (pt) |
| AT (1) | ATE390130T1 (pt) |
| AU (1) | AU1559500A (pt) |
| BR (1) | BR9916190A (pt) |
| CA (1) | CA2355300A1 (pt) |
| CZ (1) | CZ20012125A3 (pt) |
| DE (2) | DE19858253A1 (pt) |
| HK (1) | HK1041647B (pt) |
| HR (1) | HRPK20010442B1 (pt) |
| HU (1) | HUP0200152A3 (pt) |
| IL (1) | IL143717A0 (pt) |
| NO (1) | NO20012976L (pt) |
| NZ (1) | NZ512408A (pt) |
| PL (1) | PL349511A1 (pt) |
| RU (1) | RU2238090C2 (pt) |
| SK (1) | SK8562001A3 (pt) |
| TR (1) | TR200101750T2 (pt) |
| WO (1) | WO2000035429A1 (pt) |
| ZA (1) | ZA200103620B (pt) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1718677E (pt) * | 2003-12-19 | 2012-07-18 | Genentech Inc | Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos |
| MX2007001470A (es) * | 2004-08-05 | 2007-03-26 | Genentech Inc | Antagonistas anti-cmet humanizados. |
| SG185966A1 (en) | 2007-06-07 | 2012-12-28 | Divergence Inc | Control of ectoparasites |
| US20100310726A1 (en) | 2009-06-05 | 2010-12-09 | Kraft Foods Global Brands Llc | Novel Preparation of an Enteric Release System |
| US9968564B2 (en) | 2009-06-05 | 2018-05-15 | Intercontinental Great Brands Llc | Delivery of functional compounds |
| US8859003B2 (en) * | 2009-06-05 | 2014-10-14 | Intercontinental Great Brands Llc | Preparation of an enteric release system |
| US20100307542A1 (en) * | 2009-06-05 | 2010-12-09 | Kraft Foods Global Brands Llc | Method of Reducing Surface Oil on Encapsulated Material |
| MX2013014687A (es) | 2011-06-30 | 2014-02-17 | Genentech Inc | Formulaciones de anticuerpo anti-c-met. |
| US8859005B2 (en) | 2012-12-03 | 2014-10-14 | Intercontinental Great Brands Llc | Enteric delivery of functional ingredients suitable for hot comestible applications |
| EP3122900A1 (en) | 2014-03-24 | 2017-02-01 | F. Hoffmann-La Roche AG | Cancer treatment with c-met antagonists and correlation of the latter with hgf expression |
| EP2957557A1 (en) * | 2014-06-17 | 2015-12-23 | Novartis Tiergesundheit AG | New compounds |
| WO2017136727A2 (en) | 2016-02-05 | 2017-08-10 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| ES2912295T3 (es) | 2016-12-09 | 2022-05-25 | Denali Therapeutics Inc | Compuestos útiles como inhibidores de RIPK1 |
| PE20200608A1 (es) * | 2017-06-30 | 2020-03-10 | Bayer Animal Health Gmbh | Nuevos derivados de azaquinolina |
| TW202334164A (zh) | 2022-01-12 | 2023-09-01 | 美商戴納立製藥公司 | （Ｓ）－５－苄基－Ｎ－（５－甲基－４－側氧基－２，３，４，５－四氫吡啶並［３，２－ｂ］［１，４］氧氮呯－３－基）－４Ｈ－１，２，４－***－３－甲醯胺的晶型 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1044116C (zh) * | 1993-11-29 | 1999-07-14 | 默里尔药物公司 | 用作il－1作用抑制剂的苯磺酰亚胺衍生物及其用途 |
| US5559026A (en) * | 1994-10-31 | 1996-09-24 | American Cyanamid Company | Genes encoding a novel family of potassium channels |
| DE19504379A1 (de) * | 1995-02-10 | 1996-08-14 | Hoechst Ag | Substituierte Benzolsulfonylharnstoffe und -thioharnstoffe, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung pharmazeutischer Präparate sowie sie enthaltende pharmazeutische Präparate |
| SK283837B6 (sk) | 1996-05-15 | 2004-03-02 | Hoechst Aktiengesellschaft | Chrómany, spôsob ich prípravy, liečivá, ktoré ich obsahujú, a ich použitie |
| DE19706675A1 (de) | 1997-02-20 | 1998-08-27 | Hoechst Ag | Sulfonamid-substituierte Chromane, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE19707656A1 (de) | 1997-02-26 | 1998-08-27 | Hoechst Ag | Sulfonamid-substituierte anellierte 7-Ring-Verbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen |
| DE19742508A1 (de) | 1997-09-26 | 1999-04-01 | Hoechst Marion Roussel De Gmbh | Sulfonamid-substituierte Chromane, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen |
| DE19742509A1 (de) | 1997-09-26 | 1999-04-01 | Hoechst Marion Roussel De Gmbh | Sulfonamid-substituierte Chromane, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen |
| DE19748469A1 (de) * | 1997-11-03 | 1999-05-06 | Hoechst Marion Roussel De Gmbh | Sulfonamid-substituierte Benzopyranderivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen |
-
1998
- 1998-12-17 DE DE19858253A patent/DE19858253A1/de not_active Withdrawn
-
1999
- 1999-12-07 TR TR2001/01750T patent/TR200101750T2/xx unknown
- 1999-12-07 RU RU2001119996/15A patent/RU2238090C2/ru not_active IP Right Cessation
- 1999-12-07 CZ CZ20012125A patent/CZ20012125A3/cs unknown
- 1999-12-07 DE DE59914712T patent/DE59914712D1/de not_active Expired - Lifetime
- 1999-12-07 WO PCT/EP1999/009547 patent/WO2000035429A1/de active IP Right Grant
- 1999-12-07 IL IL14371799A patent/IL143717A0/xx not_active IP Right Cessation
- 1999-12-07 EP EP99958170A patent/EP1140042B1/de not_active Expired - Lifetime
- 1999-12-07 HU HU0200152A patent/HUP0200152A3/hu unknown
- 1999-12-07 NZ NZ512408A patent/NZ512408A/en unknown
- 1999-12-07 AT AT99958170T patent/ATE390130T1/de not_active IP Right Cessation
- 1999-12-07 JP JP2000587750A patent/JP2002532412A/ja not_active Ceased
- 1999-12-07 CA CA002355300A patent/CA2355300A1/en not_active Abandoned
- 1999-12-07 BR BR9916190-7A patent/BR9916190A/pt not_active Application Discontinuation
- 1999-12-07 AU AU15595/00A patent/AU1559500A/en not_active Abandoned
- 1999-12-07 CN CNB998145823A patent/CN1170528C/zh not_active Expired - Fee Related
- 1999-12-07 KR KR1020017007420A patent/KR20010089574A/ko not_active Application Discontinuation
- 1999-12-07 SK SK856-2001A patent/SK8562001A3/sk unknown
- 1999-12-07 PL PL99349511A patent/PL349511A1/xx not_active Application Discontinuation
- 1999-12-15 AR ARP990106411A patent/AR021690A1/es unknown
- 1999-12-16 US US09/461,806 patent/US6335363B1/en not_active Expired - Lifetime
-
2001
- 2001-05-04 ZA ZA200103620A patent/ZA200103620B/en unknown
- 2001-06-14 HR HR20010442A patent/HRPK20010442B1/xx not_active IP Right Cessation
- 2001-06-15 NO NO20012976A patent/NO20012976L/no not_active Application Discontinuation
- 2001-11-16 US US09/987,809 patent/US20020055537A1/en not_active Abandoned
-
2002
- 2002-05-04 HK HK02103407.9A patent/HK1041647B/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20010089574A (ko) | 2001-10-06 |
| HK1041647A1 (en) | 2002-07-19 |
| CA2355300A1 (en) | 2000-06-22 |
| IL143717A0 (en) | 2002-04-21 |
| WO2000035429A1 (de) | 2000-06-22 |
| HUP0200152A3 (en) | 2003-01-28 |
| SK8562001A3 (en) | 2001-12-03 |
| EP1140042B1 (de) | 2008-03-26 |
| EP1140042A1 (de) | 2001-10-10 |
| JP2002532412A (ja) | 2002-10-02 |
| HRP20010442A2 (en) | 2002-06-30 |
| NO20012976D0 (no) | 2001-06-15 |
| CN1330540A (zh) | 2002-01-09 |
| NZ512408A (en) | 2003-10-31 |
| NO20012976L (no) | 2001-08-06 |
| HUP0200152A2 (hu) | 2002-05-29 |
| US6335363B1 (en) | 2002-01-01 |
| DE19858253A1 (de) | 2000-06-21 |
| AR021690A1 (es) | 2002-07-31 |
| HRPK20010442B1 (en) | 2003-10-31 |
| TR200101750T2 (tr) | 2002-01-21 |
| BR9916190A (pt) | 2001-09-11 |
| CZ20012125A3 (cs) | 2001-09-12 |
| RU2238090C2 (ru) | 2004-10-20 |
| DE59914712D1 (de) | 2008-05-08 |
| HK1041647B (zh) | 2005-04-01 |
| AU1559500A (en) | 2000-07-03 |
| PL349511A1 (en) | 2002-07-29 |
| CN1170528C (zh) | 2004-10-13 |
| US20020055537A1 (en) | 2002-05-09 |
| ATE390130T1 (de) | 2008-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200103620B (en) | Utilization of inhibitors of the KQT1 channel in order to produce a medicament for treating diseases which are caused by parasitic helminths and extoparasites. | |
| FI84821C (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara, i synnerhet pao det centrala nervsystemet inverkande 5h-2,3-bensodiazepin-derivat. | |
| ZA200200464B (en) | Phosphate transport inhibitors. | |
| SK282276B6 (sk) | Benzoxazinónové deriváty, farmaceutické prostriedky s ich obsahom a ich použitie | |
| JP2004518628A (ja) | 窒素含有化合物およびそれらのグリシン輸送阻害薬としての使用法 | |
| EP0137343B1 (en) | Novel oxopyrimidine derivatives and pharmaceutical compositions containing them | |
| RU2001119996A (ru) | Применение ингибиторов kqt1-каналов для получения лекарственного средства для лечения заболеваний, вызванных гельминтами и эктопаразитами | |
| CA2408667A1 (en) | Phosphate transport inhibitors | |
| EP1059090A1 (en) | Remedies for brain infarction | |
| WO2019231739A1 (en) | Compounds for pain treatment, compositions comprising same, and methods of using same | |
| US20030216449A1 (en) | Phosphate transport inhibitors | |
| EP2470270A1 (en) | Compounds for treatment of inflammation | |
| RU2300532C2 (ru) | Производные бензо[g]хинолина для лечения глаукомы и близорукости, способ их получения и фармацевтическая композиция | |
| BR112023003792A2 (pt) | Derivados de sulfamoil ureia contendo porção alquil-oxacicloalquila e usos dos mesmos | |
| US4079130A (en) | Antidepressant phenylazoimidazoles | |
| RU98104586A (ru) | Сульфонамидзамещенные аннелированные семичленные циклические соединения, их применение в качестве лекарственного средства, а также содержащие их фармацевтические композиции | |
| AU727216B2 (en) | Sulfonamide-substituted compounds, processes for their preparation, their use as a medicament or diagnostic, and medicament comprising them | |
| JPH0314517A (ja) | うつ状態の治療のためのクロモン誘導体の使用 | |
| CA2885262A1 (en) | Coumarin derivative for treating arthropathies | |
| KR20220124682A (ko) | 모발 성장을 유도하기 위한 이타코네이트 및 이의 유도체/유사체의 용도 | |
| KR20050108402A (ko) | 만성 피부 질환의 치료제 및/또는 예방제 | |
| EP4161916A1 (en) | Substituted isoquinolinylmethyl amides, analogues thereof, and methods using same | |
| US20060035959A1 (en) | Pharmaceutical formulations containing substituted 2-aryl-aminoacetic acid compounds and/or substituted 2-heteroaryl-aminoacetic acid compounds | |
| CN117143040A (zh) | 一种环丁烯二酮基苯并恶唑衍生物及其制备方法和应用 | |
| JPH0474121A (ja) | インターロイキン１産生阻害剤 |